Clinical Trial

A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Adult Obese/Overweight Subjects

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated November 25, 2025 (before its estimated May 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a multicenter, randomized, double-blind, placebo-controlled phase III clinical study in adult obese/overweight subjects in China to evaluate the efficacy and safety of GZR18 Injection in the subjects.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-12-10.
Status change: Not Yet Recruiting → Active, Not Recruiting 2025-11-20
Trial Details
NCT Number NCT06728124
Lead Sponsor Gan & Lee Pharmaceuticals.
Conditions Obesity/Overweight
Enrollment 630 participants
Start Date 2024-12-30
Primary Completion 2026-05 (estimated)
Study Completion 2026-05 (estimated)
Updated on ClinicalTrials.gov 2025-11-25